Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 7Recruiting 5Terminated 4Unknown 3Withdrawn 2Approved for marketing 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

keyhole-limpet hemocyanin 1Vaccines 1Stem Cell Transplantation 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Nerve Tissue × Clear all
NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT02745756 2017-08-30

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
CNS

Neoplasms, Neoplasms, Nerve Tissue, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡